<DOC>
	<DOCNO>NCT00747097</DOCNO>
	<brief_summary>The purpose phase II study ass efficacy combine chemotherapy use gemcitabine cetuximab advance cholangiocarcinoma , exclude gallbladder cancer .</brief_summary>
	<brief_title>Gemcitabine Cetuximab Patients With Advanced Metastatic Biliary Tract Cancer : A Multicenter Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>histologically cytologically prove locally advanced metastatic unresectable adenocarcinoma biliary tract sign write informed consent age &gt; 18 WHO PS 0 1 study entry measurable ( diameter Â³ 1 cm ) / evaluable disease , accord RECIST criterion adequate renal ( serum creatinin &lt; 1.5x upper reference range ) , liver ( total bilirubin &lt; 2x upper reference range ) hematopoietic function ( PMN &gt; 1,5x109/L , platelet &gt; 100x109/L ) life expectancy least 12 week effective contraception throughout study male female patient risk conception exists uncontrolled concurrent CNS , cardiac , infectious disease previous exposure epidermal growth factor target therapy know hypersensitivity component study treatment previous chemotherapy cancer previous malignancy last past 5 year except basal cell cancer skin preinvasive cancer cervix pregnancy breast feed medical psychological condition would permit patient complete study sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>